ADAR1 Capital Management LLC Has $470,000 Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

ADAR1 Capital Management LLC lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,067 shares of the company's stock after selling 255,118 shares during the period. ADAR1 Capital Management LLC's holdings in Vir Biotechnology were worth $470,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company's stock worth $42,135,000 after buying an additional 530,645 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Vir Biotechnology by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company's stock valued at $16,127,000 after acquiring an additional 7,827 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company's stock worth $9,194,000 after purchasing an additional 118,379 shares during the last quarter. Artisan Partners Limited Partnership acquired a new position in Vir Biotechnology in the fourth quarter worth $6,742,000. Finally, Barclays PLC increased its stake in Vir Biotechnology by 1.3% during the third quarter. Barclays PLC now owns 550,186 shares of the company's stock valued at $4,121,000 after purchasing an additional 7,287 shares during the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on VIR. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. JPMorgan Chase & Co. increased their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. HC Wainwright reissued a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, February 28th. Finally, Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $35.67.

Vir Biotechnology Price Performance

VIR stock traded up $0.25 on Friday, reaching $5.53. The company's stock had a trading volume of 1,216,013 shares, compared to its average volume of 1,338,147. The firm has a fifty day moving average of $7.68 and a two-hundred day moving average of $8.18. The company has a market capitalization of $758.40 million, a P/E ratio of -1.41 and a beta of 1.14. Vir Biotechnology, Inc. has a 52 week low of $4.95 and a 52 week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. The company had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the transaction, the chief executive officer now owns 769,505 shares of the company's stock, valued at $4,578,554.75. The trade was a 9.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 99,611 shares of company stock worth $663,525. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).